As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...

As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...

Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy manufacturing. The collaboration merges Avantor’s bioprocessing expertise ...

Fresenius and Charles River Laboratories are among 18 academic, research, industry and clinical partners that have formed a new European Union-supported consortium to develop an automated, ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. For decades, advanced medical breakthroughs have followed a familiar ...

Avantor Inc. (NYSE:AVTR) is one of the best large cap stocks to buy under $20. On October 15, Avantor announced a partnership with BlueWhale Bio, which is a commercial-stage company that transforms ...

Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene ...

After recalibrating its production strategy in the late 2010s to better meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential ...

Chimeric antigen receptor T cell (CAR T) therapies have transformed the treatment of blood cancers, delivering durable responses in patients with limited options. But CAR T therapies are complex and ...

Researchers at Columbia University’s Sadelain lab and University Hospital Tubingen used CRISPR gene editing to knock out the ...